Our Team
Meet our team
Our dedicated team comprises leading experts in oncology, medical research and photodynamic therapy. Together, they bring a wealth of experience and a shared vision to innovate and improve cancer treatment.
Prof Bridgeen Callan
Co-Founder & CEO
An expert in pharmaceutics, pharmaceutical sciences and photodynamic therapy, Bridgeen leads Klas Therapeutics with strategic vision and growth.
Dr. Poullette Rabut Oduor
COO
Highly skilled and possesses expert knowledge of drug delivery, pharmaceutics and pharmaceutical sciences.
Dr. Rubeta Matin
CMO
Dr Rubeta Matin is a UK trained consultant dermatologist and honorary senior lecturer in Oxford since 2015.
Prof John Callan
Co-Founder & CTO
A leading figure in medical technology, John oversees the development and implementation of our innovative therapies.
Our Mission and Vision
KLAS Therapeutics’ mission is to revolutionize the treatment of melanoma skin cancer using our patented KLAS-PDT technology, with multiple other future potential applications, to provide hope for the future of patients with melanoma and other types of cancer. The team is focused on researching and developing KLAS proprietary technology, stemming from the inventors’ 10-year work at Ulster University, for applications in oncology to treat diseases of global relevance.
KLAS Therapeutics’ vision is to become the first company to develop and market a highly safe and effective therapy for malignant melanoma.
Get in touch with our team
If you’d like to connect with the Klas Therapeutics team or learn more about our ground-breaking technology, get in touch with us today.